Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344994 · ClinicalTrials.gov registry record · Phase 4
SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
A Phase 4 study, sponsored by Augusta University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00344994 is a Phase 4 study that has completed, run by Augusta University. The registered enrollment target is 20 participants.
The verdict
NCT00344994, a Phase 4 study, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the equipotent dose of ropinirole and pramipexole for patients switched from pramipexole to ropinirole in patients with moderate to severe primary Restless Legs Syndrome (RLS). The rationale behind Switch is that patients with Restless Legs Syndrome can maintain stable efficacy and tolerability if correctly switched from one dopamine agonist to an equipotent dose of another.
Interventions
- DRUG pramipexole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00344994
The ClinicalTrials.gov registry entry for NCT00344994 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pramipexole is the first listed.
NCT00344994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00344994 about?
NCT00344994 is a clinical study titled "SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole". The purpose of this study is to determine the equipotent dose of ropinirole and pramipexole for patients switched from pramipexole to ropinirole in patients with moderate to severe primary Restless Legs Syndrome (RLS). The rationale behind Switch is that patients with Restless Legs Syndrome can main...
What is the current status of trial NCT00344994?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-05. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00344994?
The interventions under investigation include: pramipexole (DRUG).
Who is sponsoring clinical trial NCT00344994?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.